What the Options Market Tells Us About Gilead Sciences
What the Options Market Tells Us About Gilead Sciences
High-rolling investors have positioned themselves bullish on Gilead Sciences (NASDAQ:GILD), and it's important for retail traders to take note.\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in GILD often signals that someone has privileged information.
高额投资者已将自己定位为看好吉利德科学(纳斯达克股票代码:GILD),散户交易者注意这一点很重要。\ 这项活动今天通过Benzinga对公开期权数据的追踪引起了我们的注意。这些投资者的身份尚不确定,但是GILD的如此重大变动通常表明有人拥有特权信息。
Today, Benzinga's options scanner spotted 19 options trades for Gilead Sciences. This is not a typical pattern.
今天,本辛加的期权扫描仪发现了吉利德科学的19笔期权交易。这不是典型的模式。
The sentiment among these major traders is split, with 84% bullish and 15% bearish. Among all the options we identified, there was one put, amounting to $93,009, and 18 calls, totaling $1,310,925.
这些主要交易者的情绪分歧,84%看涨,15%看跌。在我们确定的所有期权中,有一个看跌期权,金额为93,009美元,还有18个看涨期权,总额为1,310,925美元。
Expected Price Movements
预期的价格走势
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $75.0 to $85.0 for Gilead Sciences during the past quarter.
分析这些合约的交易量和未平仓合约,看来大型企业一直在关注吉利德科学在过去一个季度的价格范围从75.0美元到85.0美元不等。
Analyzing Volume & Open Interest
分析交易量和未平仓合约
In today's trading context, the average open interest for options of Gilead Sciences stands at 2517.0, with a total volume reaching 18,469.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $75.0 to $85.0, throughout the last 30 days.
在当今的交易背景下,吉利德科学期权的平均未平仓合约为2517.0,总交易量达到18,469.00。随附的图表描绘了过去30天吉利德科学高价值交易的看涨期权和看跌期权交易量以及未平仓合约的变化,行使价走势从75.0美元到85.0美元不等。
Gilead Sciences 30-Day Option Volume & Interest Snapshot
吉利德科学30天期权交易量和利息快照
Significant Options Trades Detected:
检测到的重要期权交易:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
GILD | CALL | SWEEP | BEARISH | 01/16/26 | $13.25 | $12.95 | $13.0 | $75.00 | $635.7K | 1.2K | 490 |
GILD | CALL | TRADE | BULLISH | 11/15/24 | $8.45 | $8.3 | $8.45 | $75.00 | $190.9K | 1.5K | 239 |
GILD | PUT | SWEEP | BULLISH | 10/18/24 | $1.29 | $1.25 | $1.29 | $80.00 | $93.0K | 2.8K | 824 |
GILD | CALL | SWEEP | BULLISH | 09/20/24 | $2.8 | $2.71 | $2.8 | $80.00 | $55.8K | 10.5K | 2.2K |
GILD | CALL | SWEEP | BEARISH | 09/20/24 | $1.39 | $1.15 | $1.15 | $83.00 | $45.9K | 142 | 927 |
符号 | 看跌/看涨 | 交易类型 | 情绪 | Exp。日期 | 问 | 出价 | 价格 | 行使价 | 总交易价格 | 未平仓合约 | 音量 |
---|---|---|---|---|---|---|---|---|---|---|---|
金 | 打电话 | 扫 | 粗鲁的 | 01/16/26 | 13.25 美元 | 12.95 美元 | 13.0 美元 | 75.00 美元 | 635.7 万美元 | 1.2K | 490 |
金 | 打电话 | 贸易 | 看涨 | 11/15/24 | 8.45 美元 | 8.3 美元 | 8.45 美元 | 75.00 美元 | 190.9 万美元 | 1.5K | 239 |
金 | 放 | 扫 | 看涨 | 10/18/24 | 1.29 美元 | 1.25 美元 | 1.29 美元 | 80.00 美元 | 93.0 万美元 | 2.8K | 824 |
金 | 打电话 | 扫 | 看涨 | 09/20/24 | 2.8 美元 | 2.71 美元 | 2.8 美元 | 80.00 美元 | 55.8 万美元 | 10.5K | 2.2K |
金 | 打电话 | 扫 | 粗鲁的 | 09/20/24 | 1.39 美元 | 1.15 美元 | 1.15 美元 | 83.00 美元 | 45.9 万美元 | 142 | 927 |
About Gilead Sciences
关于吉利德科学
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
吉利德科学开发和销售治疗危及生命的传染病的疗法,其产品组合的核心重点是艾滋病毒和乙型和丙型肝炎。吉利德对Pharmasset的收购为丙型肝炎药物Sovaldi带来了版权,后者也是保持护理标准的新组合方案的一部分。吉利德还通过收购扩大其在肿瘤市场的影响力,收购的牵头是CAR-T细胞疗法Yescarta/Tecartus(来自Kite)和乳腺癌和膀胱癌疗法Trodelvy(来自Immunomedics)。
After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
在对围绕吉利德科学的期权交易进行了全面审查之后,我们将对该公司进行更详细的审查。这包括评估其当前的市场状况和表现。
Present Market Standing of Gilead Sciences
吉利德科学目前的市场地位
- With a trading volume of 4,190,255, the price of GILD is up by 2.2%, reaching $82.72.
- Current RSI values indicate that the stock is may be overbought.
- Next earnings report is scheduled for 54 days from now.
- GILD的交易量为4,190,255美元,上涨了2.2%,达到82.72美元。
- 当前的RSI值表明该股可能已被超买。
- 下一份收益报告定于54天后发布。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
与仅交易股票相比,期权是一种风险更高的资产,但它们具有更高的获利潜力。严肃的期权交易者通过每天自我教育、扩大交易规模、关注多个指标以及密切关注市场来管理这种风险。